Abstract
A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown pharmacological effects. This article reviews heterogeneous pharmacological properties of NSAIDs including inhibitory effect against nitric oxide synthesis, agonistic action for peroxisome proliferator-activated receptor γ, or possible suppressive effects against dopamine quinone generation, and also reviews their neuroprotective effects in the experimental parkinsonian models and pathogenesis of Parkinsons disease. Several epidemiological studies recently clarified that the use of nonaspirin NSAIDs but not aspirin was associated with a lower prevalence of Parkinsons disease, in contrast with neuroprotective effects of aspirin in the experimental studies. It also discusses the discrepancy between results in the experimental parkinsonian models and epidemiological data in prevalence of Parkinsons disease on the effects of NSAIDs.
Keywords: Cyclooxygenase, dopamine quinone, inflammation, neuroprotection, nitric oxide, nonsteroidal anti-inflammatory drugs, Parkinson's disease, peroxisome proliferator-activated receptor γ
Current Pharmaceutical Design
Title: Nonsteroidal Anti-Inflammatory Drugs in Experimental Parkinsonian Models and Parkinsons Disease
Volume: 14 Issue: 14
Author(s): Masato Asanuma and Ikuko Miyazaki
Affiliation:
Keywords: Cyclooxygenase, dopamine quinone, inflammation, neuroprotection, nitric oxide, nonsteroidal anti-inflammatory drugs, Parkinson's disease, peroxisome proliferator-activated receptor γ
Abstract: A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown pharmacological effects. This article reviews heterogeneous pharmacological properties of NSAIDs including inhibitory effect against nitric oxide synthesis, agonistic action for peroxisome proliferator-activated receptor γ, or possible suppressive effects against dopamine quinone generation, and also reviews their neuroprotective effects in the experimental parkinsonian models and pathogenesis of Parkinsons disease. Several epidemiological studies recently clarified that the use of nonaspirin NSAIDs but not aspirin was associated with a lower prevalence of Parkinsons disease, in contrast with neuroprotective effects of aspirin in the experimental studies. It also discusses the discrepancy between results in the experimental parkinsonian models and epidemiological data in prevalence of Parkinsons disease on the effects of NSAIDs.
Export Options
About this article
Cite this article as:
Asanuma Masato and Miyazaki Ikuko, Nonsteroidal Anti-Inflammatory Drugs in Experimental Parkinsonian Models and Parkinsons Disease, Current Pharmaceutical Design 2008; 14 (14) . https://dx.doi.org/10.2174/138161208784480153
DOI https://dx.doi.org/10.2174/138161208784480153 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Minimal Access Surgery for Infants and Children
Current Pediatric Reviews An Image-Based Biosensor Assay Strategy to Screen for Modulators of the microRNA 21 Biogenesis Pathway
Combinatorial Chemistry & High Throughput Screening Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Design, Synthesis, and Anti-Neuroinflammatory Activity of Amide- Containing Dithiolethiones
Medicinal Chemistry An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion Inhibitors
Current Medicinal Chemistry Clinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Current Clinical Pharmacology Prodigiosins as Anti Cancer Agents: Living Upto Their Name
Current Pharmaceutical Design Novel Drug Delivery Systems for Releasing Growth Factors to the CNS: Focus on Alzheimer`s and Parkinson`s Diseases
Mini-Reviews in Medicinal Chemistry Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Redox Chemistry of Green Tea Polyphenols: Therapeutic Benefits in Neurodegenerative Diseases
Mini-Reviews in Medicinal Chemistry Recent Advances in Enone and NO-Releasing Derivatives of Oleanolic Acid with Anti-cancer Activity
Mini-Reviews in Organic Chemistry Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology Interplay Between Cholesterol and Homocysteine in the Exacerbation of Amyloid-β Toxicity in Human Neuroblastoma Cells
CNS & Neurological Disorders - Drug Targets Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Agonist-Trafficking and Hallucinogens
Current Medicinal Chemistry Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Clinical Pharmacokinetic and Metabolism of PET Radiotracers for Imaging P-glycoprotein in Chemoresistant Tumor of Colorectal Cancer
Current Drug Metabolism Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry